Literature DB >> 16392725

Dyslipidemia in HIV patients.

Marisa Tungsiripat1, Judith A Aberg.   

Abstract

Thanks to antiretroviral therapy, people with human immunodeficiency virus (HIV) infection are living longer, but as they do, non-HIV medical problems become more relevant. In particular, dyslipidemia, an important reversible risk factor for cardiovascular disease, has been linked to HIV infection and its treatment. Although controversy remains as to whether people with HIV infections will develop premature coronary heart disease, it seems prudent to manage dyslipidemia in these patients just as we do in our HIV-negative patients. Interactions between lipid-lowering drugs and antiretroviral drugs require special attention.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16392725     DOI: 10.3949/ccjm.72.12.1113

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  4 in total

1.  Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087.

Authors:  Scott R Evans; Carl J Fichtenbaum; Judith A Aberg
Journal:  HIV Clin Trials       Date:  2007 Jan-Feb

Review 2.  Cardiovascular complications in HIV management: past, present, and future.

Authors:  Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

3.  Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

Authors:  Sara Melzi; Laura Carenzi; Maria Vittoria Cossu; Simone Passerini; Amedeo Capetti; Giuliano Rizzardini
Journal:  Cholesterol       Date:  2010-10-31

4.  Apolipoprotein B Gene Polymorphisms and Dyslipidemia in HIV Infected Adult Zimbabweans.

Authors:  Vitaris Kodogo; Danai Tavonga Zhou; Olav Oektedalen; Kerina Duri; Babill Stray-Pedersen; Exnevia Gomo
Journal:  Open AIDS J       Date:  2016-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.